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BACKGROUND: Major depressive disorder (MDD) is a disabling mood disorder, and despite a known heritable
component, a large meta-analysis of genome-wide association studies revealed no replicable genetic risk variants.
Given prior evidence of heterogeneity by age at onset in MDD, we tested whether genome-wide signiﬁcant risk
variants for MDD could be identiﬁed in cases subdivided by age at onset.
METHODS: Discovery case-control genome-wide association studies were performed where cases were stratiﬁed
using increasing/decreasing age-at-onset cutoffs; signiﬁcant single nucleotide polymorphisms were tested in nine
independent replication samples, giving a total sample of 22,158 cases and 133,749 control subjects for subsetting.
Polygenic score analysis was used to examine whether differences in shared genetic risk exists between earlier and
adult-onset MDD with commonly comorbid disorders of schizophrenia, bipolar disorder, Alzheimer’s disease, and
coronary artery disease.
RESULTS: We identiﬁed one replicated genome-wide signiﬁcant locus associated with adult-onset (.27 years) MDD
(rs7647854, odds ratio: 1.16, 95% conﬁdence interval: 1.11–1.21, p 5 5.2 3 10-11). Using polygenic score analyses, we
show that earlier-onset MDD is genetically more similar to schizophrenia and bipolar disorder than adult-onset MDD.
CONCLUSIONS: We demonstrate that using additional phenotype data previously collected by genetic studies to
tackle phenotypic heterogeneity in MDD can successfully lead to the discovery of genetic risk factor despite
reduced sample size. Furthermore, our results suggest that the genetic susceptibility to MDD differs between
adult- and earlier-onset MDD, with earlier-onset cases having a greater genetic overlap with schizophrenia and
bipolar disorder.
Keywords: Age at onset, GWAS, Heterogeneity, Major depressive disorder, Polygenic scoring, StratiﬁcationISShttp://dx.doi.org/10.1016/j.biopsych.2016.05.010& 2016 Society of Biological Psychiatry. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Genomic Analysis of Age at Onset in Depression
Biological
PsychiatryMajor depressive disorder (MDD) is a highly prevalent and
heterogeneous disorder (1). With most individuals experi-
encing recurrent episodes throughout life (2), MDD is now
the second leading cause of disability worldwide (3). MDD is
deﬁned by low mood and energy, inability to experience
enjoyment, changes to eating and sleep patterns, feelings
of guilt or worthlessness, and suicidal thoughts (4). Along
with excess mortality and increased risk of suicide (5), MDD
is associated with worse clinical outcomes when comorbid
with health problems such as cardiovascular disease and
cancer (6,7). Although the heritability is estimated at 31% to
42% (8), the causal variants remain elusive: a recent large
mega-analysis with over 9000 MDD cases failed to identify
any replicable associations (9), despite successes in sim-
ilarly sized studies of schizophrenia (SCZ) and bipolar
disorder (BPD) (10,11). This lack of biological markers may
be among the causes for the well-established underfund-
ing of research into MDD relative to its economic and
health burden (12) and the reported stigmatization of suffer-
ers (13).
However, several differences exist between MDD and other
psychiatric disorders in which replicable genetic associations
have been identiﬁed, including higher prevalence, greater
diagnostic uncertainty, lower heritability, and, crucially,
increased heterogeneity. One known source of heterogeneity
that may contribute substantially is age at onset (AAO). Onset
can occur at any stage of life, yet many factors associated with
MDD are either age speciﬁc or age restricted. These include
biological events such as puberty, menopause, and dementia,
and environmental risk factors including childhood maltreat-
ment, childbirth, and divorce. Earlier onset is associated with
increased risk in ﬁrst-degree relatives and with higher heritability
(14–18). Considerable differences in the transmission of early-
versus late-onset MDD have also been reported (19,20), with
some studies suggesting the effects of novel genetic risk
factors for MDD appearing later in life (21,22).
Here we build on the previous mega-analysis of the Major
Depressive Disorder Working Group of the Psychiatric
Genomics Consortium (PGC-MDD), using AAO to stratify
cases within a sample of 8920 cases and 9521 control
subjects, with the goal of reducing heterogeneity. For each
of the nine PGC-MDD samples (23–30), cases were ordered by
AAO within study and divided into eight groups (octiles).
Genome-wide association analysis of cases in these octiles
was performed systematically against control subjects for
1,235,109 autosomal single nucleotide polymorphisms (SNPs).
We examined three analytic strategies: 1) genetic variants
speciﬁc to early-onset MDD; 2) risk variants speciﬁc to late-
onset MDD; and 3) restricting to the intermediate four octiles
excluding the 25% of cases at either extreme of AAO to test
for potential heterogeneity introduced from very early or very
late onset. Signiﬁcantly associated SNPs were taken forward
for replication in nine studies comprising 13,238 cases and
124,230 control subjects. We also examined the differences
between early- and late-onset MDD in their shared heritability
with commonly comorbid disorders of schizophrenia, bipolar
disorder, Alzheimer’s disease, and coronary artery disease
to identify differences in genetic etiologies across onset
groups.2 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalMETHODS AND MATERIALS
Description of Samples
Full details of the studies that form the PGC-MDD are given in
the supplementary materials of the original data analysis (9).
Brieﬂy, these nine MDD studies (23–30) conducted genome-
wide genotyping on individual subjects of European ancestry.
Subjects were required to have diagnoses of DSM-IV lifetime
MDD established using structured diagnostic instruments
from direct interviews by trained interviewers or clinician-
administered DSM-IV checklists. Two studies required recur-
rent MDD and one study required recurrent, early-onset MDD.
Studies ascertained cases mostly from clinical sources, and
control subjects were largely randomly selected from the
population and screened for lifetime history of MDD. This led
to a total of 9238 cases and 9521 control subjects with
genotype information.
AAO Phenotype
AAO was deﬁned as the age at which individuals ﬁrst had
symptoms that met the criteria of MDD and was self-reported in
all studies. Of the original 9238 cases included in the sample,
8920 (95.6%) had a reported AAO. Cases reporting an AAO
older than the recorded age at interview were removed from the
analysis (n = 17). Within each study, cases were ordered by
AAO and then divided into octiles, giving approximately 1000
cases per octile. Octiles were deﬁned within each study to
account for differences in case ascertainment. We noted a wide
range in AAO between studies ascertaining recurrent depres-
sion using the same instrument, indicating that the precise
setting (study, clinic, country) was important; we therefore
chose to order cases by AAO within each study, rather than
across studies, or by absolute AAO cutoffs. This strategy will
identify genetic variants that were speciﬁc to early or late onset,
relative to the mean AAO of the recruited cases. For secondary
analysis of sex-speciﬁc effects, octiles were additionally deﬁned
within only male and female subjects for analysis of sex-speciﬁc
effects, and for recurrent depression that has a higher herit-
ability. These octiles will be referred to as O1 to O8, with O1
representing the earliest onset octile and O8 representing the
latest onset octile. The GenRED (Genetics of Recurrent Early-
Onset Depression) study only recruited MDD cases with an
AAO below 31 years (25). We compared the distribution of AAO
in GenRED with other similar studies (STAR*D [Sequenced
Treatment Alternatives to Relieve Depression], RADIANT-UK)
and estimated that GenRED recruited the youngest cases (62%
of all possible MDD cases), with older cases absent from the
study (Supplemental Figure S1). GenRED cases were ordered
by AAO and assigned to the appropriate octiles O1 to O5, with
no cases present in O6 to O8.
Quality Control
Genotyping was described in the supplementary materials in
the original analysis (11). All samples were genotyped with
SNP arrays of at least 200,000 SNPs. SNPs were removed for
missingness .0.02, case-control difference in SNP missing-
ness .0.02, SNP frequency difference from HapMap3 (phase
three of the International HapMap Project) .0.15, or deviation
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p , 1.0 3 10–6). Subjects were removed for excessive
missingness (.0.02), for being identical or closely related to
any subject in any sample (p̂ . .2 based on common
autosomal SNPs), or if there was evidence for diverging
ancestry. Ancestry was estimated using multidimensional
scaling applied to 8549 SNPs directly genotyped in all
samples and in approximate linkage equilibrium. Imputation
was performed using Beagle 3.0.440 (31) with the CEU
HapMap3 data (32) to impute 1,235,109 autosomal SNP
allele dosages. The ﬁrst 20 ancestry-informative principal
components were included as covariates, along with an
indicator for each study.
Genome-wide Association Analysis
Genome-wide association analysis was performed in PLINK
using logistic regression to test the association between case-
control phenotype and imputed SNP dosages under an
additive model (33). Genotyping coordinates are given in NCBI
Build 36/UCSC hg18 (National Center for Biotechnology
Information, Bethesda, MD). Quality control was conducted
separately for each sample. To test for SNPs associated with
distinct aspects of MDD based on AAO, we performed three
hypothesis-driven analyses (Supplemental Figure S2). The ﬁrst
analysis targeted those SNPs associated with early-onset
MDD in a series of genome-wide association analyses, initially
looking at the earliest onset cases (O1) against all control
subjects, then the combined O1 and O2 cases against control
subjects, then O1 to O3, etc., until all cases were included.
This approach was based on the sequential additions method
(34), which was developed to account for a quantitative trait
that is measured in cases but not control subjects and provide
an estimate of the best phenotype deﬁnition for future studies.
The second analysis was similarly performed to examine those
SNPs associated with later-onset MDD, but reversing the
procedure (i.e., ﬁrst looking at the latest-onset cases [O8]
against all control subjects, then O7–O8 against control
subjects, then O6–O8, etc., until all cases were included).
The third analysis tested whether the extremes of AAO, both
early and late, were introducing heterogeneity to the cases
excluding O1 to O2 and O7 to O8, leaving those cases with
onset within the interquartile range of AAO for each study (O3–
O6). We then tested O3 to O6 cases against all control
subjects. Each analysis was performed using all cases, male
cases only, female cases only, and recurrent cases only.
Analyses of all, or almost all, cases (O1–O8, O1–O7, or O2–
O8) were used to identify SNPs that reached greatest signiﬁ-
cance without an AAO-speciﬁc effect and so were omitted
from further analysis as would have been captured in the
primary analysis of this data. In total, 52 genome-wide
analyses were performed [5 (6 1 6 1 1) 3 4], making the
standard multiple testing threshold of p , 5.0 3 10–8 for
genome-wide signiﬁcance anticonservative. We applied a
Bonferroni correction for 52 analyses to genome-wide signiﬁ-
cance, which is highly conservative because many analyses
were highly correlated. For replication, we selected SNPs with
p , 9.5 3 10–10 in the discovery sample in more than one
analysis (either by sex or recurrence or inclusion of octiles); the
combination of cases that yielded the greatest signiﬁcancewas chosen as the basis for replication. This analysis strategy
uses AAO as a stratifying variable to construct subsets of cases
that may be more homogeneous and identify SNPs that are
associated with susceptibility to MDD with a restricted AAO;
it does not identify SNPs that control MDD AAO, which would
require a case-only analysis of AAO as a quantitative trait.
Replication Analysis
Five replication samples used in the primary analysis of this
dataset had AAO information available [TwinGene (35), GenREDII/
DepGenesNetwork (25), deCODE (9), PsychCoLaus (36), SHIP-
LEGEND (Study of Health in Pomerania–Life-Events and Gene-
Environment Interaction in Depression) (37)]. The GenPod/NEW-
MEDS and Harvard i2b2 studies, which appeared in the repli-
cation of the primary analysis of this dataset, did not have AAO
data available and were not included. Four new replication studies
were available: 1) a collection of samples available through the
University of Münster (38,39); 2) a combination of RADIANT cases
from Denmark (40), the Danish DEMO and PRISME studies of
MDD (41,42), and a set of Danish population control subjects; 3)
the CONVERGE (China Oxford and VCU Experimental Research
on Genetic Epidemiology) study of MDD cases and control
subjects recruited in China (18,43,44); and 4) the Generation
Scotland study, which included measures on MDD (45). These are
outlined, alongside the deﬁnitions of AAO, in Supplemental
Methods. Due to the early median AAO in the GenREDII/
DepGenesNetwork, an artiﬁcial “median” was introduced at age
27 years, based on the median for the discovery samples. Those
SNPs that passed our threshold of p , 9.5 3 10–10 in the
discovery sample were tested for association within these nine
replication studies. Due to differences in availability of genome-
wide genotype data, each study was genotyped and/or imputed
separately. A ﬁxed-effect inverse variance based meta-analysis of
the replication studies was performed using METAL (46).
Polygenic Analysis
We also examined the association between early- and late-onset
MDD and polygenic risk scores for other psychiatric disorders, as
this might reﬂect either shared genetic etiology or phenotypic
contamination (47). Polygenic risk scores for schizophrenia (9379
cases and 7736 control subjects) and bipolar disorder (6990
cases and 4820 control subjects) were created by the PGC,
using imputed data and removing overlapping control subjects,
ensuring that the datasets were completely independent (10,11).
Alzheimer’s disease polygenic risk scores were obtained from
the GERAD (Genetic and Environmental Risk for Alzheimer’s
disease) Consortium (48) and the coronary artery disease scores
from the CARDIoGRAM Consortium (49). The imputed GERAD
sample comprised 3177 cases and 7277 control subjects, and
the CARDIoGRAM consortium consisted of 22,233 cases and
64,762 control subjects. All four disorders were chosen for their
previous genetic and epidemiological evidence of overlap with
MDD (50–52).
Polygenic risk scores were calculated for MDD cases and
control subjects, summing the number of risk alleles carried,
weighted by the natural log of their odds ratio in the original
genome-wide association study (GWAS). Score SNPs with low
minor allele frequency (,0.02) or in the major histocompati-
bility complex region were removed, and score datasets wereBiological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journal 3
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mand in PLINK to remove SNPs within 500 kb and
r2 . .25 with a more signiﬁcantly associated SNP. Seven
scores were calculated, using a p value threshold (PT) to
restrict to the most signiﬁcant SNPs in their original genome-
wide association analysis (PT , .01, .05, .1, .2, .3, .4, .5).
Logistic regression was used to test for association between
polygenic risk scores and case-control status using four
different case-control sets (all MDD cases vs. control subjects,
O1–O3 cases vs. control subjects, O6–O8 cases vs. control
subjects, and O1–O3 cases vs. O6–O8 cases) with 20 population
principal components and study indicators as covariates. We
calculated the proportion of variance explained (Nagelkerkeʼs R2)
by subtraction of a full model (covariates 1 polygenic risk
score) from a reduced model (covariates only). The GenRED
sample was not included in the analysis as they had no cases
within the O6–O8 analysis; the Bonn-Mannheim study was not
included in the analysis of Alzheimer’s disease or coronary artery
disease due to overlapping control subjects with the respective
consortia.RESULTS
Summary of AAO
After quality control, the sample consisted of 8920 MDD cases
with AAO information and 9519 control subjects with
1,235,109 SNPs. The median AAO across all cases excluding
GenRED was 27 years old (interquartile range: 18, 38) and the
mean 28.9 613.64, reﬂecting the long tail of older onset cases
(Figure 1 and Supplemental Figure S3). Median AAO by study
ranged from 20 to 37 years (16 for GenRED, which recruited
only recurrent cases with onset no greater than 30), with the
German samples having a slightly older onset. Mean AAO wasFigure 1. Distribution of age at onset across the nine studies included in
the discovery analysis. Mid-gray band shows interquartile range across all
studies excluding GenRED (Genetics of Recurrent Early-Onset Depression),
which recruited only cases onset at 30 years or less. GAIN, Genetic
Association Information Network; GSK, GlaxoSmithKline; MPIP, Max Planck
Institute of Psychiatry; NESDA, Netherlands Study of Depression and
Anxiety; NTR, Netherlands Twin Register.
4 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journallower for recurrent than nonrecurrent cases, 27.1 to 33.0 (p ,
.001, correcting for study and excluding GenRED). AAO was
also older for male subjects with a mean of 29.0 compared
with 26.7 in female subjects (p , .001).
Genome-wide Association Analysis
Our analysis of both early- and late-onset octiles and the
intermediate median of AAO excluding extreme-AAO cases led
to four tests passing our signiﬁcance cutoff for replication (p ,
9.5 3 10–10), all for associations with SNP rs7647854 on
chromosome 3. The only genome-wide signiﬁcant association
for this SNP was in the 50% oldest onset cases against all
control subjects (O5–O8: p5 3.4 3 10-11) (Supplemental Figures
S4 and S5). As a secondary analysis of this SNP, we split cases
within our discovery sample into nonoverlapping quartiles and
analyzed them against control subjects. This showed a strong
association in the oldest quartile (O7–O8: p 5 9.0 3 10–10, odds
ratio [OR]: 1.37, 95% conﬁdence interval [CI]: 1.23–1.51)
(Figure 2), a moderate effect in the third quartile (O5–O6: p 5
2.0 3 10–5, OR: 1.23), and no evidence of association in the two
youngest quartiles (O1-O2: p 5 .07, OR: 1.09; O3-O4: p 5 .30,
OR: 1.06). Furthermore, when the inclusion threshold for AAO
was increased 1 year at a time within each study (until only 100
cases remained), we observed a gradual increase in effect size
for rs7647854 in all studies as the analysis was restricted to
progressively later onset cases (Supplemental Figure S6). Anal-
ysis by sex or recurrence revealed no additional ﬁndings.
Replication Analysis
Given the results from our discovery dataset, rs7647854 was
taken forward for replication in nine independent studies
(Table 1). The SNP was tested for association with oldest half
of MDD cases (O5–O8), because this analysis attained the
smallest p value in the discovery studies. The SNP was either
directly genotyped or imputed at high conﬁdence across all
studies (Supplemental Table S1). The SNP was signiﬁcantly
associated with MDD in a meta-analysis of these studies,
with a p value of 7.5 3 10–4 and an OR of 1.10 (total number
of MDD cases 5 6107 and total number of control subjects
124,230) (Table 2; Supplemental Figure S5). Meta-analysis of
the combined discovery sample with individual replica-
tion studies gave a p value of 5.2 3 10–11 and an OR of 1.16
(95% CI: 1.11–1.21), surpassing genome-wide signiﬁcance.
Polygenic Analysis of Comorbid Illnesses
In the PGC-MDD discovery studies, polygenic risk scores for
BPD and SCZ were signiﬁcantly associated with early-onset
MDD. Restricting to only early-onset cases (O1-O3) versus
control subjects, the amount of phenotypic variability explained
(BPD: R2 5 .41%, p 5 1.4 3 10–12; SCZ: R2 5 .67%, p 5 3.0
3 10–19) was much greater than for later onset (O6–O8) cases
(BPD: R2 5 .16%, p 5 1.9 3 10–5; SCZ: R2 5 .14%, p 5 3.9
3 10–5) (Figure 3). A similar increase in association with late-
onset comorbid disorders was not seen. Polygenic risk scores
for coronary artery disease from the CARDIoGRAM Consortium
(49) were weakly positively associated with MDD, but this was
consistent across early and late onset cases, in contrast to BPD
and SCZ (coronary artery disease: O1–O3 cases vs. control
subjects, R2 5 .05%, p 5 .01; O6–O8 cases vs. control
Figure 2. Evidence for association
and effect size for rs7647854 on
chromosome 3, with cases split into
nonoverlapping quartiles by age at
onset within discovery studies. O,
octile.
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R2 # .01%, p 5 .76) (Figure 3). No association with MDD status
was seen for the scores generated for Alzheimer’s disease from
the GERAD Consortium (48) regardless of AAO (O1–O3 casesTable 1. Summary of MDD Discovery and Replication Cohorts
Study Country Measu
Discovery NESDA/NTR (GAIN) The Netherlands CIDI
GenRED United States DIGS3
GSK Germany SCAN
MDD2000-QIMR_610 Australia CIDI/SS
MDD2000-QIMR_317 Australia CIDI/SS
MPIP Germany Asked a
RADIANT Bonn/Mannheim Germany SCAN
RADIANT United Kingdom SCAN
STAR*D United States Asked a
Total
Replication TwinGene Sweden SALT
PsyCoLaus Switzerland DIGS
SHIP-LEGEND Germany M-CIDI
GenRED2/DepGenesNetworks United States DIGS3
University of Münster Germany SCID
Combined Danish sample Denmark SCAN
CONVERGE China
deCODE Iceland Hospita
Generation Scotland United Kingdom SCID
Total
Total
AAO, age at onset; CONVERGE, China Oxford and VCU Experimenta
Diagnostic Interview; DIGS, Diagnostic Interview for Genetic Studies; GA
Recurrent Early-Onset Depression; GSK, GlaxoSmithKline; M-CIDI, Munich
disorder; MPIP, Max Planck Institute of Psychiatry; NESDA, Netherlands Stu
Screening Across the Lifespan Twin; SCAN, Schedules for Clinical Assess
Disorders; SHIP-LEGEND, Study of Health in Pomerania–Life-Events and G
Assessment for the Genetics of Alcoholism; STAR*D, Sequenced Treatmenvs. control subjects, R2 , .01%, p 5 .868; O6–O8 cases vs.
control subjects, R25 .02%, p5 .223; O1–O3 cases vs. O6–O8
cases, R2 5 .03%, p 5 .157) (Figure 3). Full results from these
analyses are available in Supplemental Tables S2 and S3.re of AAO Cases With AAO Control Subjects Median AAO
1675 1765 25
1020 1253 16
887 864 36
AGA 432 751 26
AGA 1015 960 26
t interview 373 537 37
883 1290 33
1407 1588 20
t interview 1228 511 21
8920 9519
1009 8601 40
1358 1687 33
381 1827 37
1296 930 17
402 516 27
461 1197 31
5715 5537 34
l records 1005 99,175 39
1611 4760 30
13,238 124,230
22,158 133,749
l Research on Genetic Epidemiology; CIDI, Composite International
IN, Genetic Association Information Network; GenRED, Genetics of
-Composite International Diagnostic Interview; MDD, major depressive
dy of Depression and Anxiety; NTR, Netherlands Twin Register; SALT,
ment in Neuropsychiatry; SCID, Structured Clinical Interview for DSM
ene-Environment Interaction in Depression; SSAGA, Semi-Structured
t Alternatives to Relieve Depression.
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Table 2. Summary of Association With rs7647854, Located
at 3q27.2 (186359477 Base Pairs), With Odds Ratio for the
Reference Allele, G (Frequency 0.16) Compared With the
Nonreference Allele A
Study
MDD
Cases, n
Control
Subjects, n OR (95% CI) p Value
Discovery 3869 9519 1.30 (1.20–1.40) 3.4 3 10–11
Replication 6107 124,230 1.10 (1.05–1.17) 7.5 3 10–4
Meta-analysis 9976 133,749 1.16 (1.11–1.21) 5.2 3 10–11
All results reported are for the oldest half of MDD cases (O5-8), which
had the strongest evidence for association in the discovery study.
CI, conﬁdence interval; MDD, major depressive disorder; OR, odds ratio.
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Our analysis of AAO and the genetic architecture of MDD
suggested that AAO-speciﬁc genetic risk factors exist. Unex-
pectedly, the strongest associations we observed were with
the oldest half of MDD cases, where previous analyses have
focused on early-onset MDD, supported by studies of the
genetic epidemiology of MDD. We emphasize that here “late”-
onset MDD was at still a relatively young age (median onset of
MDD was at age 27 years with 98% of our sample having
onset before 60 years) rather than onset in old age. It is clearer
to conceptualize later-onset cases here as “adult-onset”
cases, and we recommend that this subgroup should be
included in recruitment of future genetic studies, especially
as no difference in the heritability captured by SNPs was
observed for this subtype compared with early-onset cases
(see Supplemental Table S3). However, substantial differences
in AAO across studies make it difﬁcult to put a precise age
cutoff for this recommended adult-onset MDD.
We show signiﬁcant association with rs7647854 on chromo-
some 3, which was associated with the 50% latest-onset cases
(OR: 1.16, p 5 5.2 x 10–11). This SNP was identiﬁed as the
second strongest association in the primary mega-analysis of
the PGC-MDD dataset (9), though at a much lower signiﬁcance,
and did not replicate (discovery p 5 6.5 3 10–7, replication
p 5 .67). Stratifying by AAO leads to much stronger associations
in both the discovery and replication samples, despite the
reduced sample size. Although analyzing across multiple over-
lapping AAO subtypes runs the risk of overﬁtting to maximize
signiﬁcance, we observed highly signiﬁcant associations for this
SNP in both discovery and replication samples. Furthermore, we
also observed a gradual increase in effect size as both raw AAO
within studies and AAO percentile across studies increased
(Figure 2, Supplemental Figure S4). That this was seen both
for raw AAO within studies and as a percentile, and in both
European and Chinese ancestry studies across a wide variety of
AAO measurement tools, suggests that whereas our cutoff of the
50% latest onset cases is arbitrary, the effect exists regardless of
exact cutoff used. However, this does not rule out the possibility
that AAO may be a proxy for a more homogenous subgroup of
MDD based on another factor (e.g., an age-speciﬁc environ-
mental trigger or distinct pattern of symptoms with onset later in
life). That median AAO and effect size across studies was not
signiﬁcantly correlated (r 5 .011, p 5.68) despite greater effect
sizes by AAO percentile within studies suggests that differences
in measurement of AAO across studies might obscure effects.6 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalrs7647854 is intergenic, with ﬂanking genes including C3orf70,
VPS8, EHHADH, and MAP3K13. C3orf70, VPS8, and MAP3K13
all show evidence of expression in the brain in several areas of
potential interest for MDD including the hypothalamus, frontal
cortex, pituitary, and thyroid (GTEx; http://www.gtexportal.org/)
(53). VPS8 and MAP3K13 also show a slight increase in RNA
expression within various brain regions during neonatal develop-
ment (Human Brain Transcriptome; http://hbatlas.org/) (54) with
maintained expression into adulthood.
This genetic association arises with the supposedly less
heritable form of adult-onset MDD, although such summary
measures give no information on the effect sizes of individual
SNPs. One potential explanation is greater contamination of
early-onset MDD cases by individuals misclassiﬁed with MDD
or having comorbid disorders. Longitudinal studies show that
early-onset depressive symptoms predict not only adult
depression but also psychosis [e.g., (55)], and there is signiﬁ-
cant genetic overlap between MDD and other psychiatric
disorders (50). Inclusion of early-onset cases with individuals
who will later develop SCZ or BPD would reduce the power of
GWASs for MDD, though secondary analysis of age at interview
did not support this (Supplemental Figure S7). The polygenic
risk score results show that early- and adult-onset MDD cases
differ in their genetic susceptibility to BPD and SCZ and
suggest that some of the heterogeneity in MDD results from
the inclusion of early-onset cases with a greater genetic overlap
or misclassiﬁcation with these disorders. We did not observe a
similar pattern of association for two disorders that are often
comorbid with late-onset MDD, Alzheimer’s disease, and
coronary artery disease (51,52). We did, however, show for
the ﬁrst time a genetic overlap between MDD and coronary
artery disease irrespective of AAO but no overlap between MDD
and Alzheimer’s disease. We also found that the heritability
explained by SNPs across the genome for early- and late-onset
MDD did not signiﬁcantly differ, suggesting, for common
variants at least, that recruiting only early-onset cases would
not increase power (Supplemental Table S3).
The limitations of our approach are the reduced sample size
and multiple testing from stratifying cases into subtypes, and
requiring potentially less reliable secondary phenotypes to be
widely collected. Measures such as AAO rely on self-report
and are often assessed differently across studies, which can
be problematic for comparison. The analyses presented here
addressed this by analyzing AAO relative to the median of a
study, though this assumed that each study recruited cases
from the same distribution of onset with observed differences
due to how AAO was deﬁned. Furthermore, the effect of our
genome-wide associated SNP were consistent in the replica-
tion studies, ethnicities, and countries, suggesting that differ-
ences in measurement may not be as much of a limitation as
expected, at least in the case of AAO in MDD. The other
disadvantage of looking at more homogenous groups is the
reduction in sample size. However, it has previously been
shown that only modest increases in effect size may be
required to offset the reduction in power from analyzing fewer
cases, implying that analyses of more homogenous subgroups
have the potential to identify novel associations (56).
Our study illustrates the value of using additional pheno-
typic information on cases in GWASs. We show here that
including information on AAO increases the power to detect
Figure 3. Polygenic risk proﬁle scoring analysis of bipolar disorder, schizophrenia, Alzheimer’s disease, and coronary artery disease within the major
depressive disorder (MDD) discovery studies (excluding GenRED [Genetics of Recurrent Early-Onset Depression]). We calculated the proportion of variance
explained (Nagelkerkeʼs R2) by subtraction of a full model (covariates 1 polygenic risk score) from a reduced model (covariates only). AAO, age at onset; O,
octile; PGC, Psychiatric Genomics Consortium.
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Psychiatryassociations with MDD, and that analyzing polygenic risk
scores from related diseases enables us to identify sources
of phenotypic heterogeneity that may have hampered previous
genetic studies. In contrast to other approaches that weight
cases on AAO (57), our stratiﬁcation of cases on AAO is
agnostic to the direction of the phenotypic effect. Our
approach uses the additional phenotype data previously
collected by genetic studies and complements an alternative
emphasis on collecting large sample sizes through minimal
phenotyping. Both strategies will undoubtedly be necessary to
identify and characterize different components of the genetic
architecture of psychiatric disorders. Furthermore, our analysis
shows that tackling phenotypic heterogeneity in MDD can
successfully lead to the discovery of a genetic risk factor
despite reduced sample size. The identiﬁcation here of a novel
genetic risk variant for MDD is of great importance due to both
the scarcity of evidence for the underlying biology and its
pressing economic health burden.ACKNOWLEDGMENTS AND DISCLOSURES
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